Nanoscope to show 3-year MCO-010 data as BLA sits with FDA
The ASRS presentation adds durability follow-up to a trial that already reported its primary result, arriving after Nanoscope says it has submitted a BLA for the gene therapy in retinitis pigmentosa.
Executive Summary
- Nanoscope will show longer-term follow-up data from its completed retinitis pigmentosa trial at a major retina conference, adding durability evidence to a program that already reported its primary result and that the company says has an active BLA before the FDA.
- The AppliedXL model reads this program with wide uncertainty on whether the endpoint result will be judged clinically significant, reflecting the trial's small size and the single-digit weeks of endpoint follow-up rigor it was built on, even as regulatory-approval odds sit higher.
- MCO-010 has no direct competitor sharing its opsin-based mechanism in retinitis pigmentosa, leaving it to compete against a broader field of gene-therapy candidates targeting different genes, none of which have reached Nanoscope's regulatory stage.
- The conference presentation itself does not alter the regulatory or competitive picture; the substance to track is whether the 3-year data sustain the vision gains that supported the BLA submission, or reveal decline.
The presentation
Benjamin Bakall will present the 3-year REMAIN follow-up data from RESTORE, the Phase 2b/3 trial of MCO-010 (NCT04945772), as a paper-on-demand session at the ASRS 44th Annual Scientific Meeting in Montreal, running July 15-18, 2026. RESTORE enrolled 27 adults with advanced retinitis pigmentosa in a randomized, double-masked, sham-controlled design, comparing a single intravitreal injection of MCO-010 against sham across two experimental arms and one sham comparator arm. The trial completed in 2024, and Nanoscope has separately reported that at Week 52 a majority of MCO-010-treated patients improved by two or more luminance levels on a mobility test, which the company characterized as clinically meaningful and statistically significant. The conference session extends that record to three years of follow-up. Press Release+1Press ReleaseJul 10, 2026Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]NCT04945772
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Regulatory backdrop
MCO-010 holds FDA Fast Track and Orphan Drug designations for retinitis pigmentosa, both recorded in October 2022. Nanoscope's own materials state a BLA has been submitted to the FDA for MCO-010 in retinitis pigmentosa, and describe the therapy as a one-time, in-office intravitreal injection that does not require genetic testing. No FDA approval record for MCO-010 exists yet. The company has also disclosed plans for a Phase 3 registrational trial of MCO-010 in Stargardt disease. Press ReleasePress ReleaseJul 10, 2026
Trial history
RESTORE's primary completion date moved three times in the registry, from January 2023 to March 2023 to March 28, 2023, before settling at February 27, 2023, and the trial reached Completed status in March 2024. Enrollment held flat at its target of 27 patients, a change the operational model treats as within the routine band rather than as a departure from plan. The trial's registry-churn rate registers as Moderate on amendment frequency, driven mostly by the completion-date revisions rather than by enrollment or population changes. NCT04945772Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]NCT04945772
Competitive frame
No other trial in retinitis pigmentosa targets opsin the way MCO-010 does; the closest direct comparator, Zuretinol Acetate, shares the target but is a small molecule tested in age-related macular degeneration, not retinitis pigmentosa. Among gene-therapy peers in retinitis pigmentosa, none target opsin: Ocugen's OCU400 (RHO) has reached Phase 3, while AbbVie's RST-001, Sanofi's SAR421869, and Novartis's CPK850 all remain in Phase 1/2 against other targets. Of four completed trials in the opsin-by-retinitis-pigmentosa pairing across two sponsors, none has terminated, and the field has seen zero active trials and zero recent starts against 36 older trials in the broader opsin category, a pattern the landscape data describe as field decline rather than active competition. Press ReleasePress ReleaseJul 10, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.